FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
This article was originally published in The Tan Sheet
Executive Summary
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
You may also be interested in...
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
Crawford Nomination Suggests Stability For Supplements, OTC Regulation
Confirmation of Lester Crawford as permanent FDA commissioner would provide the consumer health industries with a known variable for at least the next four years
CDER’s Galson Says Statin Switches May Be Ready For A Second Look
The time may be right for FDA to revisit statins as a possible Rx-to-OTC switch category of drugs, according to Acting CDER Director Steve Galson, MD